BRII-B

Tengshengbo Pharmaceutical is a biotechnology company dedicated to developing treatments that can solve major public health challenges. Amidst these challenges, large numbers of patients' medical needs are unmet, choices are limited, and social stigma is severe. Since its establishment in 2018, Tengsheng Pharmaceuticals's mission has been to address public health challenges through groundbreaking scientific innovation and insightful patient insight. Tengshengbo Pharmaceutical's mission is very clear: to develop a functional cure for hepatitis B, Tengsheng Pharmaceutical believes this can have a meaningful impact on patients in China and around the world.

Tengshengbo Pharmaceutical is cooperating with its partners to promote a strong portfolio of HBV drug candidates, strategically positioning itself as a leading company in the HBV field. The product portfolio includes three differentiated drug candidates: elebsiran (a siRNA under development targeting HBV, previously BRII-835), tobevibart (a broadly neutralizing monoclonal antibody under development, formerly BRII-877), and BRII-179 (a vaccine for HBV treatment based on recombinant proteins). These drug candidates are being tested for various combination treatment options, and each combination treatment may be the best treatment plan aimed at improving the functional cure rate of HBV.

Data obtained over the past few years strongly confirm that functional cure for HBV is possible for patients with low HBsAg levels. The combination strategy of Tengshengbo Pharmaceutical combines surface antigen reduction therapy with immunomodulatory therapy to improve the effectiveness of HBV treatment and improve the functional cure rate. Encouraged by the latest data readings and insights, Tengshengbo Pharmaceuticals is advancing all three drug candidates and plans to conduct additional trials by the end of 2024.

Based on recognition of the innovation of Tengshengbo Pharmaceutical's HBV product portfolio, all three HBV drug candidates have been certified as breakthrough therapeutic varieties by the Drug Evaluation Center of the China National Drug Administration. These certifications recognize the potential of these candidate drugs to make substantial progress on existing therapies and will accelerate their clinical development and regulatory review.

While concentrating resources to maximize the impact of HBV clinical programs, Tengshengbo Pharmaceutical is also actively seeking partners to further develop its non-HBV programs, including HIV, MDR/XDR, and CNS programs.